Figure 2.
Comparison of mean cost‐by‐cost category between rifampicin mono‐resistant/MDR‐TB cases and MDR‐TB with second‐line resistance (including XDR‐TB). RIF‐mono, rifampicin mono‐resistance; MDR‐TB, multidrug‐resistant TB; PHC, primary health care; USD, US dollars.